Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD
Information source: University Health Network, Toronto
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tourette's Syndrome; Attention Deficit Hyperactivity Disorder
Intervention: APO-clonidine (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University Health Network, Toronto Official(s) and/or principal investigator(s): Robyn J Stephens, PhD.C.Psych., Principal Investigator, Affiliation: Youthdale Treatment Centres
Overall contact: Robyn J Stephens, PhD. C.Psych, Phone: 416-368-4896, Ext: 2260, Email: rstephens@youthdale.ca
Summary
In the present study, we examine the question “Will day-time aggression in children improve
when their night-time sleep is treated with pharmacological intervention (i. e. clonidine)?”
There is considerable anecdotal evidence that clonidine may provide an effective alternative
to neuroleptics for treating aggression in children - - first by improving the overall
quality of their sleep, and second by providing a safer and more readily tolerated
medication with fewer side-effects and a greater probability of long-term compliance. This
study uses a double blind placebo controlled design to gather scientific evidence that will
help elucidate the mechanisms underlying this treatment effect and will help clarify the
relationship between sleep disorders and aggression in children. Our results are expected
to help physicians make informed treatment decisions regarding the use of clonidine to
improve the quality of sleep and possibly treat problems with aggression in their pediatric
patients
Clinical Details
Official title: Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Objective: The differences between baseline and final polysomnographic sleep architecture measurements.
Secondary outcome: Subjective:Differences in scores from baseline to trial end on the Sleep Disturbance Scale for Children, the Children's Sleep habits Questionnaire, and scales of Aggressive or maladaptive behaviour (Parent,Teacher and Self reports).
Detailed description:
Background: Childhood sleep disturbance is pervasive, yet remains under-treated and one of
the most poorly researched areas in pediatric psychopharmacology. Of particular concern is
the growing evidence of an association between sleep disturbance and aggression in children.
Childhood aggression is a serious public health problem and predicts adolescent
delinquency, academic difficulties and truancy, and substance abuse. Children with
Tourette’s syndrome (TS) and co-morbid attention deficit hyperactivity disorder (ADHD) will
be studied in a trial of a common pharmacological treatment (clonidine) that is expected to
improve sleep architecture and thereby clarify the relation between sleep disturbance and
aggression.
Hypothesis: Our main hypothesis is that improvement in children’s sleep will be associated
with a reduction in their aggression and an increase in their daily function.
Method: A double-blind placebo controlled trial with 32 subjects (aged 9-14 years) with
diagnoses of TS & co-morbid ADHD. Subjects will undergo a mental health assessment, ECG,
laboratory testing and 2-night polysomnography (sleep study) at baseline. Subjects will
then be randomized to a treatment (clonidine) or placebo group for an 8-week trial.
Clonidine will be titrated and subjects monitored weekly. A second 2-night sleep study and
mental health assessment will occur at trial end.
Expected results: We expect an improvement in the initial onset, duration and overall sleep
quality in the treatment group (clonidine), with a resulting decrease in daytime aggression
and increase in daily overall level of functioning; sleep and aggression in the placebo
group are not expected to improve.
Eligibility
Minimum age: 9 Years.
Maximum age: 14 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females
- Meet the DSM-III-R criteria for Tourette syndrome based on the assessment of a study
psychiatrist and the presence of comorbid Attention Deficit Hyperactivity Disorder
(ADHD) according to DSM-IV diagnostic criteria
- A negative history of psychiatric illness that requires treatment.
- Medication free for a minimum period of six (6) weeks at the time of entry into the
study
- Between the ages of 9: 0 years and 14: 11 years
- An initial screening score on the Children’s Aggression Scale-Parents Version of at
least +1SD above average on at one or more of the four subscales.
- Adequate English language comprehension and production (sufficient to respond to
questions from the investigators)
- Be able and willing to cooperate with the study protocol
- All parents/caregivers will provide consent and subjects (children/adolescents) will
give their informed assent prior to participating in any study procedures.
- Known history of sleep disturbances (children will be considered to experience sleep
disturbances if their sleep latency regularly exceeds 30 minutes; to have a general
poor quality of sleep if there are frequent awakenings (>2 nightly), nightmares or
restlessness; or if they experience difficulty awakening, marked difficulty with
arousal or consistent oversleeping. For the purposes of this study, a disturbance in
sleep is considered only if it is chronic (lasting more than one month) and frequent
(two or more times per week).
Exclusion Criteria:
*Evidence of Pervasive Developmental Disorder, known seizure disorder, history of severe
head trauma, post-traumatic stress disorder, depression, known organic basis for a sleep
disorder and/or an estimated Full Scale Intellectual Quotient below 85
Locations and Contacts
Robyn J Stephens, PhD. C.Psych, Phone: 416-368-4896, Ext: 2260, Email: rstephens@youthdale.ca
Youthdale Treatment Centres, Toronto, Ontario M5B 1T8, Canada; Recruiting Robyn J Stephens, PhD. C.Psych, Phone: 416-368-4896, Ext: 2874, Email: rstephens@youthdale.ca Robyn J Stephens, PhD. CPsych, Principal Investigator Paul Sandor, MD, FRCPC, Sub-Investigator Colin M Shapiro, MD, FRCPC, Sub-Investigator
Additional Information
Youthdale Treatment Centres
Starting date: September 2006
Ending date: October 2008
Last updated: February 27, 2007
|